Compare WORX & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WORX | HCWB |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 3.8M |
| IPO Year | N/A | 2021 |
| Metric | WORX | HCWB |
|---|---|---|
| Price | $0.24 | $1.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 11.5M | 79.4K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,784,479.00 | $422,026.00 |
| Revenue This Year | N/A | $178.64 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.18 | $0.95 |
| 52 Week High | $1.84 | $41.20 |
| Indicator | WORX | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 66.99 | 43.54 |
| Support Level | $0.18 | $1.25 |
| Resistance Level | $0.19 | $1.65 |
| Average True Range (ATR) | 0.02 | 0.14 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 53.31 | 42.86 |
SCWorx Corp is a provider of data content and services related to the repair, normalization, and interoperability of information for healthcare providers, as well as big data analytics for the healthcare industry. Its software enables a healthcare provider to simplify and organize its data, allows the data to be utilized across multiple internal software applications, and provides the basis for sophisticated data analytics. The company has developed and markets healthcare information technology solutions and associated services to improve healthcare processes and information flow within hospitals and other healthcare facilities.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.